| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,341,563 | 18 | 100 |
| Astley-Sparke Philip | director | 0 | $0 | 1 | $89,698 | $-89,698 |
| Schwendenman Andrew | Chief Accounting Officer | 0 | $0 | 2 | $139,089 | $-139,089 |
| Sarchi Christopher | Chief Commercial Officer | 0 | $0 | 4 | $254,158 | $-254,158 |
| Xynos Konstantinos | Chief Medical Officer | 0 | $0 | 3 | $285,661 | $-285,661 |
| Hill Emily Luisa | Chief Financial Officer | 0 | $0 | 3 | $320,341 | $-320,341 |
| Dhingra Kapil | director | 0 | $0 | 2 | $441,458 | $-441,458 |
| Patel Sushil | Chief Executive Officer | 0 | $0 | 3 | $811,159 | $-811,159 |
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase …
Over the last 12 months, insiders at Replimune Group, Inc. have bought $0 and sold $2.34M worth of Replimune Group, Inc. stock.
On average, over the past 5 years, insiders at Replimune Group, Inc. have bought $0 and sold $2.67M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,100,000 shares for transaction amount of $14.97M was made by Rhodes Jason P (director) on 2019‑11‑18.
| 2026-11-02 | Sale | Dhingra Kapil | director | 21,500 0.0199% | $19.00 | $408,500 | +8.68% | |
| 2026-08-17 | Sale | Hill Emily Luisa | Chief Financial Officer | 9,256 0.0093% | $14.28 | $132,176 | -9.77% | |
| 2026-08-10 | Sale | Patel Sushil | Chief Executive Officer | 39,341 0.0402% | $12.97 | $510,253 | -3.11% | |
| 2026-08-10 | Sale | Hill Emily Luisa | Chief Financial Officer | 11,448 0.0117% | $12.97 | $148,481 | -3.11% | |
| 2026-08-10 | Sale | Xynos Konstantinos | Chief Medical Officer | 11,447 0.0117% | $12.97 | $148,468 | -3.11% | |
| 2026-08-10 | Sale | Schwendenman Andrew | Chief Accounting Officer | 7,632 0.0078% | $12.97 | $98,987 | -3.11% | |
| 2026-06-01 | Sale | Sarchi Christopher | Chief Commercial Officer | 12,000 0.0149% | $9.24 | $110,880 | +34.56% | |
| 2026-05-18 | Sale | Astley-Sparke Philip | director | 17,657 0.0217% | $5.08 | $89,698 | +136.93% | |
| 2026-05-18 | Sale | Patel Sushil | Chief Executive Officer | 37,324 0.0458% | $5.08 | $189,606 | +136.93% | |
| 2026-05-18 | Sale | Hill Emily Luisa | Chief Financial Officer | 7,812 0.0096% | $5.08 | $39,685 | +136.93% | |
| 2026-05-18 | Sale | Xynos Konstantinos | Chief Medical Officer | 14,023 0.0172% | $5.08 | $71,237 | +136.93% | |
| 2026-05-18 | Sale | Sarchi Christopher | Chief Commercial Officer | 8,626 0.0106% | $5.08 | $43,820 | +136.93% | |
| 2026-05-18 | Sale | Schwendenman Andrew | Chief Accounting Officer | 7,894 0.0097% | $5.08 | $40,102 | +136.93% | |
| 2026-04-02 | Sale | Sarchi Christopher | Chief Commercial Officer | 6,500 0.0083% | $8.01 | $52,065 | +32.94% | |
| 2025-12-09 | Sale | Dhingra Kapil | director | 3,169 0.0041% | $10.40 | $32,958 | -12.62% | |
| 2025-12-02 | Sale | Patel Sushil | Chief Executive Officer | 10,000 0.0142% | $11.13 | $111,300 | -5.05% | |
| 2025-11-17 | Sale | Xynos Konstantinos | Chief Medical Officer | 7,248 0.0096% | $9.10 | $65,957 | +8.27% | |
| 2025-11-17 | Sale | Sarchi Christopher | Chief Commercial Officer | 5,208 0.0069% | $9.10 | $47,393 | +8.27% | |
| 2025-08-15 | Sale | Hill Emily Luisa | Chief Financial Officer | 9,154 0.0113% | $5.37 | $49,157 | +42.09% | |
| 2025-05-20 | Sale | Astley-Sparke Philip | director | 32,279 0.0368% | $8.06 | $260,169 | -17.19% |
| Omega Fund IV, L.P. | 4763380 5.0246% | $98.36M | 2 | 20 | +27.98% | |
| Slootweg Hugo Alexander | 4721449 4.9804% | $97.5M | 1 | 0 | <0.0001% | |
| Forbion Capital Fund III Cooperatief U.A. | 10 percent owner | 4721449 4.9804% | $97.5M | 1 | 0 | <0.0001% |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2838968 2.9947% | $58.62M | 1 | 0 | <0.0001% |
| Rhodes Jason P | director | 946000 0.9979% | $19.53M | 1 | 11 | +63.12% |
| SLATTERY JOSEPH P | director | 6667 0.007% | $137,673.55 | 1 | 1 | <0.0001% |
$607,395,062 | 99 | 4.23% | $1.88B | |
$21,345,882 | 83 | 94.45% | $2.19B | |
$47,419,530 | 58 | 17.20% | $1.96B | |
$1,376,668 | 53 | 18.46% | $2.1B | |
$108,353,116 | 49 | 15.41% | $2.17B |
| Increased Positions | 96 | +49.74% | 19M | +22.74% |
| Decreased Positions | 87 | -45.08% | 22M | -26.55% |
| New Positions | 38 | New | 8M | New |
| Sold Out Positions | 37 | Sold Out | 10M | Sold Out |
| Total Postitions | 202 | +4.66% | 80M | -3.81% |
| Baker Bros. Advisors Lp | $98,303.00 | 14.16% | 11.05M | 0 | 0% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $73,927.00 | 10.65% | 8.31M | -3M | -23.23% | 2025-09-30 |
| Rtw Investments, Lp | $56,922.00 | 8.2% | 6.4M | +4M | +209.72% | 2025-09-30 |
| Blackrock, Inc. | $51,405.00 | 7.41% | 5.78M | +45,514 | +0.79% | 2025-09-30 |
| Fcpm Iii Services B.V. | $37,009.00 | 5.33% | 4.16M | +248,672 | +6.36% | 2025-09-30 |
| Point72 Asset Management, L.P. | $32,306.00 | 4.65% | 3.63M | +3M | +409.43% | 2025-09-30 |
| Vanguard Group Inc | $30,967.00 | 4.46% | 3.48M | +9,707 | +0.28% | 2025-09-30 |
| Tang Capital Management Llc | $30,260.00 | 4.36% | 3.4M | +200,000 | +6.25% | 2025-09-30 |
| State Street Corp | $26,025.00 | 3.75% | 2.92M | +471,437 | +19.22% | 2025-09-30 |
| Braidwell Lp | $24,476.00 | 3.53% | 2.75M | +2M | +550.31% | 2025-09-30 |